Wall Street Zen Upgrades Obsidian Therapeutics (NASDAQ:OBX) to Sell

Obsidian Therapeutics (NASDAQ:OBX) was upgraded by Wall Street Zen to a “sell” rating in a report released on Saturday, Wall Street Zen reports.

Several other equities analysts have also recently weighed in on OBX. William Blair began coverage on Obsidian Therapeutics in a report on Wednesday, September 9th. They issued an “outperform” rating for the company. Lifesci Capital started coverage on Obsidian Therapeutics in a research note on Tuesday, August 18th. They issued an “outperform” rating and a $43.00 price target for the company. TD Cowen began coverage on Obsidian Therapeutics in a research note on Thursday, August 6th. They issued a “buy” rating for the company. Weiss Ratings started coverage on shares of Obsidian Therapeutics in a research report on Wednesday, September 2nd. They set a “sell (d-)” rating for the company. Finally, Zacks Research upgraded shares of Obsidian Therapeutics to a “hold” rating in a research note on Thursday, August 6th. Four equities research analysts have rated the stock with a Buy rating, one has given a Hold rating and one has given a Sell rating to the company. According to data from MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and an average target price of $42.50.

Obsidian Therapeutics Stock Performance

Shares of OBX stock opened at $17.75 on Friday. Obsidian Therapeutics has a 1 year low of $14.57 and a 1 year high of $49.97.

About Obsidian Therapeutics

Obsidian Therapeutics Inc is a clinical-stage biopharmaceutical company harnessing novel protein-regulation technology to develop engineered TIL cell therapies for the treatment of patients with solid tumors. Obsidian Therapeutics Inc is based in CAMBRIDGE, Mass.